As of Q3'25, CVS reported SG&A Expenses of USD 11.29B, while R&D Expenses remained at USD 0. The latest data point highlights a continued absence of R&D spending and a notable increase in SG&A costs compared to previous quarters. From Q1'23 to Q3'25, the chart shows that CVS consistently allocated no funds to R&D Expenses, with all operating expenses attributed to SG&A. SG&A Expenses exhibited a steady upward trend, rising from USD 9.58B in Q1'23 to USD 11.29B in Q3'25, with a particularly sharp increase observed from Q4'23 onward. This pattern suggests a growing focus on selling, general, and administrative activities over the reported period.